778 related articles for article (PubMed ID: 28368410)
1. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1.
Cohen N; Shani O; Raz Y; Sharon Y; Hoffman D; Abramovitz L; Erez N
Oncogene; 2017 Aug; 36(31):4457-4468. PubMed ID: 28368410
[TBL] [Abstract][Full Text] [Related]
2. Chitinase 3-like 1 secreted from cancer-associated fibroblasts promotes tumor angiogenesis via interleukin-8 secretion in colorectal cancer.
Watanabe K; Shiga K; Maeda A; Harata S; Yanagita T; Suzuki T; Ushigome H; Maeda Y; Hirokawa T; Ogawa R; Hara M; Takahashi H; Matsuo Y; Mitsui A; Kimura M; Takiguchi S
Int J Oncol; 2022 Jan; 60(1):. PubMed ID: 34913066
[TBL] [Abstract][Full Text] [Related]
3. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1
Gok Yavuz B; Gunaydin G; Gedik ME; Kosemehmetoglu K; Karakoc D; Ozgur F; Guc D
Sci Rep; 2019 Feb; 9(1):3172. PubMed ID: 30816272
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast-Derived IL33 Facilitates Breast Cancer Metastasis by Modifying the Immune Microenvironment and Driving Type 2 Immunity.
Shani O; Vorobyov T; Monteran L; Lavie D; Cohen N; Raz Y; Tsarfaty G; Avivi C; Barshack I; Erez N
Cancer Res; 2020 Dec; 80(23):5317-5329. PubMed ID: 33023944
[TBL] [Abstract][Full Text] [Related]
5. Targeting protumor factor chitinase-3-like-1 secreted by Rab37 vesicles for cancer immunotherapy.
Yang PS; Yu MH; Hou YC; Chang CP; Lin SC; Kuo IY; Su PC; Cheng HC; Su WC; Shan YS; Wang YC
Theranostics; 2022; 12(1):340-361. PubMed ID: 34987649
[No Abstract] [Full Text] [Related]
6. The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment.
Monteran L; Erez N
Front Immunol; 2019; 10():1835. PubMed ID: 31428105
[TBL] [Abstract][Full Text] [Related]
7. Stromal fibroblast-derived MFAP5 promotes the invasion and migration of breast cancer cells via Notch1/slug signaling.
Chen Z; Yan X; Li K; Ling Y; Kang H
Clin Transl Oncol; 2020 Apr; 22(4):522-531. PubMed ID: 31190277
[TBL] [Abstract][Full Text] [Related]
8. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein.
Chen Y; Zhang S; Wang Q; Zhang X
J Hematol Oncol; 2017 Feb; 10(1):36. PubMed ID: 28143526
[TBL] [Abstract][Full Text] [Related]
9. Increased RUNX3 expression mediates tumor-promoting ability of human breast cancer-associated fibroblasts.
Koyama Y; Okazaki H; Shi Y; Mezawa Y; Wang Z; Sakimoto M; Ishizuka A; Ito Y; Koyama T; Daigo Y; Takano A; Miyagi Y; Yokose T; Yamashita T; Sugahara K; Hino O; Yang L; Maruyama R; Katakura A; Yasukawa T; Orimo A
Cancer Med; 2023 Sep; 12(17):18062-18077. PubMed ID: 37641472
[TBL] [Abstract][Full Text] [Related]
10. Exosomal miR-500a-5p derived from cancer-associated fibroblasts promotes breast cancer cell proliferation and metastasis through targeting USP28.
Chen B; Sang Y; Song X; Zhang D; Wang L; Zhao W; Liang Y; Zhang N; Yang Q
Theranostics; 2021; 11(8):3932-3947. PubMed ID: 33664871
[TBL] [Abstract][Full Text] [Related]
11. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling.
Yang X; Lin Y; Shi Y; Li B; Liu W; Yin W; Dang Y; Chu Y; Fan J; He R
Cancer Res; 2016 Jul; 76(14):4124-35. PubMed ID: 27216177
[TBL] [Abstract][Full Text] [Related]
12. Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.
Hu S; Ma J; Su C; Chen Y; Shu Y; Qi Z; Zhang B; Shi G; Zhang Y; Zhang Y; Huang A; Kuang Y; Cheng P
Acta Biomater; 2021 Nov; 135():567-581. PubMed ID: 34506976
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Nox4 induces a pro-survival Nrf2 response in cancer-associated fibroblasts that promotes tumorigenesis and metastasis, in part via Birc5 induction.
Mir S; Golden BDO; Griess BJ; Vengoji R; Tom E; Kosmacek EA; Oberley-Deegan RE; Talmon GA; Band V; Teoh-Fitzgerald ML
Breast Cancer Res; 2022 Jul; 24(1):48. PubMed ID: 35836253
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.
Li A; Chen P; Leng Y; Kang J
Oncogene; 2018 Nov; 37(45):5952-5966. PubMed ID: 29980788
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade.
Jenkins L; Jungwirth U; Avgustinova A; Iravani M; Mills A; Haider S; Harper J; Isacke CM
Cancer Res; 2022 Aug; 82(16):2904-2917. PubMed ID: 35749591
[TBL] [Abstract][Full Text] [Related]
16. Carcinoma associated fibroblasts (CAFs) promote breast cancer motility by suppressing mammalian Diaphanous-related formin-2 (mDia2).
Dvorak KM; Pettee KM; Rubinic-Minotti K; Su R; Nestor-Kalinoski A; Eisenmann KM
PLoS One; 2018; 13(3):e0195278. PubMed ID: 29596520
[TBL] [Abstract][Full Text] [Related]
17. CPT1C-positive cancer-associated fibroblast facilitates immunosuppression through promoting IL-6-induced M2-like phenotype of macrophage.
Wei R; Song J; Pan H; Liu X; Gao J
Oncoimmunology; 2024; 13(1):2352179. PubMed ID: 38746869
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling.
Suh J; Kim DH; Lee YH; Jang JH; Surh YJ
Mol Carcinog; 2020 Sep; 59(9):1028-1040. PubMed ID: 32557854
[TBL] [Abstract][Full Text] [Related]
19. TGFβ-specific T cells induced by a TGFβ-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblasts.
Perez-Penco M; Lara de la Torre L; Lecoq I; Martinenaite E; Andersen MH
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417917
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
